ImmunityBio Executive and Leadership Team

Frank Jones, the Chairman & Chief Executive Officer at ImmunityBio, directs the overarching strategic vision for the development of next-generation immunotherapy platforms. By aligning corporate resources with the goal of defeating cancers and infectious diseases, the Chairman & Chief Executive Officer ensures the organization maintains its status as an FDA Breakthrough Therapy innovator. This leadership role involves managing the integration of cell therapy platforms to create durable immune responses. Frank Jones oversees the transition from traditional high-dose chemotherapy toward more accessible, effective treatment standards. Through constant engagement with the Board and scientific leadership, the Chairman & Chief Executive Officer drives the expansion of the company's therapeutic pipeline. By prioritizing the activation of natural killer cells and memory T cells, the executive secures the long-term market position of the firm. Ultimately, the Chairman & Chief Executive Officer fosters a culture of scientific excellence that defines the company's impact on global oncology.

Enrique Diloné, the Chief Technology Officer at ImmunityBio, architects the technical infrastructure required to scale the production of advanced immunotherapy and vaccine candidates. Overseeing the manufacturing processes, the Chief Technology Officer ensures that the company's vertically-integrated biotechnology platforms operate with maximum efficiency. This role involves optimizing the delivery mechanisms for ANKTIVA and other pipeline assets to ensure accessibility for patients worldwide. Enrique Diloné manages the intersection of complex biological science and industrial-scale production, driving the transition away from standard high-dose chemotherapy. By implementing rigorous quality control and innovative manufacturing techniques, the Chief Technology Officer supports the company's goal of creating durable protection against disease. The Chief Technology Officer collaborates with research teams to translate laboratory breakthroughs into viable, easily administered clinical products. Through this technical leadership, the executive ensures that the company's scientific advancements reach the market with speed and precision, ultimately strengthening the firm's competitive advantage in the biotechnology sector.

Leonard Sender, the Chief Medical Officer, Liquid Tumors & Cell Therapy at ImmunityBio, directs the clinical development and medical strategy for the company's liquid tumor and cell therapy portfolios. Overseeing complex clinical trials, the Chief Medical Officer, Liquid Tumors & Cell Therapy ensures that therapeutic candidates effectively activate natural killer cells and T cells to combat malignancy. This leadership role involves close coordination with regulatory bodies to validate the efficacy of new treatments as alternatives to standard high-dose chemotherapy. Leonard Sender manages the medical oversight of patient outcomes, ensuring that the company's science translates into safe, durable protection against disease. By analyzing clinical data and refining treatment protocols, the Chief Medical Officer, Liquid Tumors & Cell Therapy drives the advancement of the company's oncology pipeline. The Chief Medical Officer, Liquid Tumors & Cell Therapy maintains a focus on improving patient quality of life through innovative immunotherapy. Through this medical expertise, the executive ensures that the company remains at the forefront of cancer research and clinical application.

Sarah Singleton, the Chief Communications Officer & Head of Patient Advocacy at ImmunityBio, directs the company's public engagement and patient-centric initiatives. Overseeing the narrative surrounding the firm's immunotherapy breakthroughs, the Chief Communications Officer & Head of Patient Advocacy ensures that the medical community and the public understand the benefits of moving beyond standard high-dose chemotherapy. This role involves building strong relationships with patient advocacy groups to ensure that the company's mission remains aligned with the needs of those facing cancer and infectious diseases. Sarah Singleton manages the dissemination of clinical trial results and corporate milestones to stakeholders, driving transparency and trust. By championing the patient perspective within the executive team, the Chief Communications Officer & Head of Patient Advocacy ensures that the company's growth strategy prioritizes accessibility and patient well-being. The Chief Communications Officer & Head of Patient Advocacy shapes the public perception of the company's innovative platforms, ultimately strengthening the brand's reputation as a leader in the biotechnology industry.